Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  temsirolimus
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-4438, B1771007, 2009-015498-11, NCT01180049
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K5-4406, B1771015, NCT01210482
Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1771016, NCT01420601
Caphosol in Oral Mucositis Due to Targeted Therapy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Esperanz-002, NCT01265810
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 341, NCT01078142
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MRHCCTS2010, NCT01335074
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: , NCT01389427
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEL001, NCT01614301
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WG2015001, NCT02423954
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201170, NCT00838955
Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TemPCNSL, EudraCT 2009-011277-33, NCT00942747
Temsirolimus-RCC-imaging
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200903, NCT01246817
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HE 21/10, 2010-020664-38, NCT01264341
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0358, NCI-2011-01277, NCT01392183
Phase II Study of Alternating Sunitinib and Temsirolimus
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: D1011, NCT01517243
Temsirolimus as Second-line Therapy in HCC
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3066K1-2247, NCT01567930
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 61 and over
Sponsor: Other
Protocol IDs: 3066K1-1165, NCT01611116
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STORM-2011, 2011-001491-20, NCT01653067
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: UCSF CC# 124511, NCT01687673
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: ESFT13, NCT01946529
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAM3801, NCT02238496
Doxil, Bevacizumab and Temsirolimus Trial
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2008-0384, NCI-2012-01665, NCT00761644
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000643294, UPCC-08908, 807931, WYETH-C-UPCC-03809, NCT00909831
A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200902, NCT00982631
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RPCI I 150709, NCI-2009-01537, NCT01174199
Start Over